GLP-1–pathway agonists such as semaglutide and newer multi-agonists have transformed care for obesity and diabetes, yet developers still wrestle with durability, tissue targeting, and signal "bias." Macrocyclization, tying part of a peptide into a ring, can shield drugs from degradation and favor bioactive shapes, but conventional chemistry can be costly and hard to apply late in development.